| Drug Type Bispecific antibody | 
| Synonyms Anti-PDL1/TGF-bifunctional fusion protein - Shandong Boan Biotechnology, BA 1201, BA-1201 + [1] | 
| Target | 
| Action inhibitors | 
| Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Gastrointestinal Neoplasms | Phase 1 | China  | 31 Oct 2022 | |
| Non-Small Cell Lung Cancer | Phase 1 | China  | 31 Oct 2022 | |
| Small Cell Lung Cancer | Phase 1 | China  | 31 Oct 2022 | |
| Transitional Cell Carcinoma | Phase 1 | China  | 31 Oct 2022 | |
| Uterine Cervical Cancer | Phase 1 | China  | 31 Oct 2022 | |
| Small Cell Carcinoma | Phase 1 | China  | 18 Jul 2022 | |
| malignant carcinoid tumor of digestive tract | Phase 1 | China  | - | |
| Uterine Corpus Cancer | Phase 1 | China  | - | 






